Abstract:Cisplatin is widely used as the standard gastric cancer treatment, but the relapse and metastasis are common as intrinsic or acquired drug resistance. CD133 has been widely known to be associated with chemoresistance in various cancer cells. In this study, we focused on investigating the function and mechanism of CD133 underlying cisplatin resistance in gastric cancer cell line KATO-III. We detected CD133 expression by using quantitative real-time polymerase chain reaction and Western blot and found that expression of CD133 was upregulated in cisplatin resistance of KATO-III cells (Cis-KATO-III) compared with KATO-III cells, indicating the role of CD133 in regulating cisplatin resistance of KATO-III cells. Then we sorted the Cis-KATO-III cells into CD133-positive (CD133 + ) pools and measured the proliferation and apoptosis after the cell is transfected with pc-CD133 and sh-CD133 by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide assay and flow cytometry. The results showed that the inhibition of CD133 inhibited the cell viability and promoted the cell apoptosis after cisplatin treatment. Furthermore, we found that inhibition of CD133 downregulated the expression of PI3K/AKT and promoted the expression of mammalian target of rapamycin, thus inhibited the autophagic activity in the Cis-KATO-III cells after cisplatin treatment. Besides, we also verified the effects of CD133 in vivo. The results indicated that inhibition of CD133 enhanced the Cis-KATO-III cell sensitivity to cisplatin by regulating PI3K/AKT/mTOR signaling pathway. In summary, our data provide new insight that CD133 activates the PI3K/AKT/mTOR signaling transduction pathway, resulting in activation of autophagy and cisplatin resistance of Cis-KATO-III cells. These results may offer a novel therapeutic target in cisplatin-resistant gastric cancer.

Overexpression of AKT decreases the chemosensitivity of gastric cancer cells to cisplatin in vitro and in vivo.

DKK1 Promotes Epithelial–Mesenchymal Transition and Cisplatin Resistance in Gastric Cancer via Activation of the PI3K/AKT Pathway

Up‐regulation of Survivin by AKT and Hypoxia‐inducible Factor 1α Contributes to Cisplatin Resistance in Gastric Cancer

Inhibition of AKT Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin by Abrogating S and G2/M Arrest.

CK1 stimulates ubiquitination-dependent proteasomal degradation of ATF4 to promote chemoresistance in gastric Cancer

Akt Inhibitor MK-2206 Enhances the Effect of Cisplatin in Gastric Cancer Cells.

The AKT1/NF-kappaB/Notch1/PTEN Axis Has an Important Role in Chemoresistance of Gastric Cancer Cells

The Impact of Akt and Nuclear Factor Kb Pathway on Chemoresistance of Gastric Cancer Cell

The AKT1|[sol]|NF-kappaB|[sol]|Notch1|[sol]|PTEN axis has an important role in chemoresistance of gastric cancer cells

Inhibition of CD133 Overcomes Cisplatin Resistance Through Inhibiting PI3K/AKT/mTOR Signaling Pathway and Autophagy in CD133-Positive Gastric Cancer Cells

Phosphoinositide 3-Kinase/akt Pathway Plays an Important Role in Chemoresistance of Gastric Cancer Cells Against Etoposide and Doxorubicin Induced Cell Death.

Inhibition of Autophagy Improves Resistance and Enhances Sensitivity of Gastric Cancer Cells to Cisplatin.

RNAi Knockdown of the Akt1 Gene Increases the Chemosensitivity of Gastric Cancer Cells to Cisplatin Both in Vitro and in Vivo

Phospho Akt Mediates Multidrug Resistance of Gastric Cancer Cells Through Regulation of P-gp, Bcl-2 and Bax.

PI3K/AKT signaling pathway as a critical regulator of Cisplatin response in tumor cells

Knockdown of RAP2A gene expression suppresses cisplatin resistance in gastric cancer cells

Pantoprazole Augments Sensitivity of Human Gastric Adenocarcinoma Cells to Cisplatin by Inhibition of Autophagy

Inhibition of JNK/c-Jun-ATF2 Overcomes Cisplatin Resistance in Liver Cancer Through Down-Regulating Galectin-1.

The Akt/Gsk3 Beta-Mediated Slug Expression Contributes To Oxaliplatin Resistance In Colorectal Cancer Via Upregulation Of Ercc1

ZIPK activates the IL‐6/STAT3 signaling pathway and promotes cisplatin resistance in gastric cancer cells

Cancer-derived IgG involved in cisplatin resistance through PTP-BAS/Src/PDK1/AKT signaling pathway